


Case: CT2749 US – NP  
 USSN 10/719,188

What is claimed is:

1. (Currently Amended) A compound of Formula I or a pharmaceutically acceptable salt thereof



wherein

R<sup>1</sup> is selected from the group consisting of pyridinyl, 3-quinolinyl, 2-thienyl,

C<sub>3-6</sub> cycloalkyl and phenyl optionally substituted with a substituent

independently selected from the group consisting of halogen, C<sub>1-4</sub> alkyl,

C<sub>1-4</sub> alkoxy, trifluoromethyl and trifluoromethoxy;

A is -CH=CH- or -(CH<sub>2</sub>)<sub>n</sub>;


R<sup>2</sup> is C<sub>1-4</sub> alkyl, CF<sub>3</sub> or hydroxymethyl;

R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> each are independently hydrogen or fluoro;

n is an integer of 1 or 2; and

B is 2-pyridinyl, 3-pyridinyl or 4-pyridinyl.

2. (Currently Amended) The compound of claim 1 ~~having the Formula II~~ or a pharmaceutically acceptable salt thereof



wherein

R<sup>1</sup> is selected from the group consisting of pyridinyl, 3-quinolinyl, 2-thienyl,

C<sub>3-6</sub> cycloalkyl and phenyl optionally substituted with a substituent

independently selected from the group consisting of halogen, C<sub>1-4</sub> alkyl,

C<sub>1-4</sub> alkoxy, trifluoromethyl and trifluoromethoxy;

Case: CT2749 US - NP  
USSN 10/719,188

- A is  $-\text{CH}=\text{CH}-$  or  $-(\text{CH}_2)_n-$ ;  
 $\text{R}^2$  is methyl or hydroxymethyl;  
 $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$  and  $\text{R}^6$  each are independently hydrogen or fluoro;  
 $n$  is an integer of 1 or 2; and  
5 B is 2-pyridinyl, 3-pyridinyl or 4-pyridinyl.

3. (Original) The compound of claim 1 selected from the group consisting of:  
  
(S)-3-phenyl-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;  
10 (S)-3-(2-fluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;  
(S)-3-(3-fluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;  
(S)-3-(2,3-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;  
15 (S)-3-(2,4-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;  
(S)-3-(2,5-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;  
20 (S)-3-(2,6-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;  
(S)-3-(3,4-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;  
(S)-3-(3,5-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;  
25 (S)-3-(2,4-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-propionamide;  
(S)-3-(3,4-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-propionamide;  
30 (S)-2-(2,5-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acetamide;  
(S)-2-(2,6-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acetamide;

Case: CT2749 US - NP  
USSN 10/719,188

(S)-2-cyclopentyl-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-  
acetamide; and

(S)-2-cyclohexyl-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-  
acetamide;

5 or a pharmaceutically acceptable salt thereof.

4. (Currently Amended) A pharmaceutical composition ~~for the treatment of disorders responsive to opening of KCNQ potassium channels~~ comprising a  
therapeutically effective amount of the compound of claim 1 in association with a  
10 pharmaceutically acceptable carrier, adjuvant or diluent.

5. (Cancelled)

6. (Currently Amended) ~~The method of claim 5~~ A method for the treatment  
15 of disorders responsive to opening of the KCNQ potassium channels in a  
mammal in need thereof, wherein said disorders are acute and chronic pain,  
migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy,  
anxiety and depression ~~and neurodegenerative disorders~~, which comprises  
administering to said mammal a therapeutically effective amount of the  
20 compound of claim 1.

7. (Original) The method of claim 6 wherein said disorder is migraine.

8. (Original) The method of claim 6 wherein said disorder is neuropathic  
25 pain.